Direct Answer
106 SEC filers are classified under the Standard Industrial Classification codes that describe the diagnostic devices industry, and their latest annual reports show $217.4 billion of combined revenue and a median operating margin of -31.5%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Diagnostic device makers produce instruments, imaging systems and test platforms that clinicians use to detect disease. Revenue includes equipment sales and recurring consumables and service contracts. The first numbers to compare across companies here are installed base and utilization, recurring consumables share and gross margin.
Key Industry Metrics
- Installed base and utilization: Number of instruments placed and how heavily they are used. Utilization drives consumable orders, so a large but idle base earns little.
- Recurring consumables share: Portion of revenue from reagents, cartridges and service. A higher share reduces dependence on equipment purchases.
- Gross margin: Share of sales left after manufacturing cost. Consumables earn more than instruments, so mix affects margin.
- Order backlog: Equipment orders accepted but not yet shipped. It gives visibility into near-term revenue and falls when hospitals delay purchases.
- Reimbursement for tests: Payment rates set by insurers and government for tests run on the devices. Lower rates reduce lab appetite for new platforms, so changes affect demand.
Primary Macro Drivers
- Health system capital budgets: Hospitals buy imaging systems and analyzers out of capital budgets, so financial strength sets order timing and backlog.
- Test volume growth: As more tests are ordered, analyzers run more often, which lifts recurring consumables and service revenue on the installed base.
- Technology cycles: New generations of systems raise demand from customers replacing older ones, which supports orders and installed base.
- Reimbursement policy: Payment rates set what labs earn per test, which affects how much they are willing to spend on instruments and consumables.
Major Risks
- Capital spending delays: Hospitals postpone equipment purchases when finances are tight, so orders and backlog fall; watch orders and installed base replacement.
- Reimbursement cuts: Lower payments per test reduce lab income and lead to cost pressure on suppliers; watch pricing commentary and consumables revenue.
- Competition: Many suppliers offer similar platforms, so deals can come with price concessions; watch gross margin and win rates.
- Regulatory clearances: New products need clearance before sale, so delays push back revenue; watch regulatory timelines and the pipeline.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | U.S. / Global |
Diagnostic Devices Filers in the SEC Record
106 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification codes 3841, 3845, 2835. Their latest fiscal years end between 2022 and 2026, and together they reported $217.4 billion of revenue. Median revenue growth over the prior year was 14.3%. Median operating margin was -31.5% and median net margin -26.2%. Median total liabilities were 47% of total assets, and 31 of 106 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Medtronic Plc | $36.4 billion | 8.4% | 17.8% | 0.0% | FY 2026 |
| Medline Inc. | $28.4 billion | 11.5% | 7.8% | 4069.4% | FY 2025 |
| Stryker Corp | $25.1 billion | 11.2% | 19.5% | 12.9% | FY 2025 |
| 3m Co | $24.9 billion | 1.5% | 18.6% | 13.0% | FY 2025 |
| Becton Dickinson & Co | $21.8 billion | 8.2% | 11.8% | 7.7% | FY 2025 |
| Boston Scientific Corp | $20.1 billion | 19.9% | 18.0% | 14.4% | FY 2025 |
| Baxter International Inc | $11.2 billion | 5.7% | -2.7% | -8.5% | FY 2025 |
| Solventum Corp | $8.3 billion | 0.9% | 26.2% | 18.7% | FY 2025 |
The 8 largest of 106 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Diagnostic Devices guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Diagnostic Laboratories
- Diabetes Devices
- Diagnostics & Post-Acute Care
- Dermatology Pharmaceuticals
- Dialysis Centers
- Dental Service Organizations
- Digital Therapeutics
- Dental Equipment
Put it to work
Frequently Asked Questions
What are the main KPIs for the Diagnostic Devices industry?
Key performance indicators for the Diagnostic Devices industry include: Installed base and utilization, Recurring consumables share, Gross margin, Order backlog, Reimbursement for tests. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Diagnostic Devices industry?
The Diagnostic Devices industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Diagnostic Devices industry?
The primary risks for Diagnostic Devices companies include: Capital spending delays, Reimbursement cuts, Competition, Regulatory clearances. Investors should assess each company's exposure to these factors and its track record of navigating them.